1. **Presentation Title -** Effect of REGEN-COV Infusions on hospitalizations secondary to COVID-19 at a Regional Community Hospital
2. **Author(s) –** Nicholas Shields, PharmD
3. **Practice Site –** Novant Health New Hanover Regional Medical Center
4. **Background Information –** The FDA authorized the use of REGEN-COV in June 2021 and shortly after COVID-19 cases were beginning to rise in the southeast. This institution noticed the as an area to have a positive impact on the community and modified an infusion clinic to meet the needs of the community by created a workflow, referral system, and protocol for the infusion of monoclonal antibodies for the treatment of COVID-19.
5. **Objective –** Evaluate the impact of NH NHRMC’s infusion clinic REGEN-COV administrations on our community during the COVID-19 pandemic
6. **Methods –** This was an IRB approved study, that consisted of a retrospective chart review for patients who received an infusion of REGEN-COV at this institution. Descriptive statistics were used analyze the data, which was compared to the closest available comparators.
7. **Preliminary Results –** There were 1444 total infusions administered. Approximately 10% (145) patients were admitted within 30 days after receiving an infusion for REGEN-COV, and death within 30 days was <1%. Looking at mortality from 31-60 days there were 45 (3.1%) more patients with a hospital admission. Comparing the overall inpatient mortality during the pandemic at this institution to the in-patient mortality in this study we see a noticeable decrease from 14.7% to 6.8% respectively. Lastly, the average length of stay in this study was lower than the total length of stay for the pandemic with a decrease from 8.69 days to 3.4 days.
8. **Conclusion –** Creating a workflow and program for REGEN-COV infusions at the clinic proved to meet the needs of our community given the total number of infusions and the amount of cases in our area. Observationally, there was a benefit in outcomes from patients that received an infusion of REGEN-COV. This innovation appears to be a success in outcomes, adaptability of this health-system and, likely, in assisting with patient loyalty.